

Frans J Van Overveld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7349576/publications.pdf>

Version: 2024-02-01

42
papers

1,107
citations

516710
16
h-index

395702
33
g-index

42
all docs

42
docs citations

42
times ranked

1315
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of Gut Microbiota on the Immune Response to Vaccination. , 2022, , 145-160.		0
2	Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines, 2021, 9, 848.	4.4	64
3	The "original antigenic sin" and its relevance for SARS-CoV-2 (COVID-19) vaccination. Clinical Immunology Communications, 2021, 1, 13-16.	1.2	19
4	Saint John on Patmos: Revelations of the Role of Antineutrophil Cytoplasmic Antibody (ANCA) in Vasculitis. Current Medicinal Chemistry, 2020, 27, 2852-2862.	2.4	0
5	Death and the Miser: microbiota regulate the outcome of checkpoint inhibition immunotherapy. Expert Review of Anticancer Therapy, 2019, 19, 831-834.	2.4	3
6	Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly. Risk Management and Healthcare Policy, 2018, Volume 11, 55-65.	2.5	4
7	The ascent of the blessed: regulatory issues on health effects and health claims for probiotics in Europe and the rest of the world. Beneficial Microbes, 2018, 9, 717-723.	2.4	14
8	Mankind Beset by Devils: On the Function of Sneezing and Coughing as a Form of Defense Against Infections. Journal of Vaccines Immunology and Immunopathology, 2018, 5, .	0.0	0
9	The long and winding road to IgA deficiency: causes and consequences. Expert Review of Clinical Immunology, 2017, 13, 371-382.	3.0	15
10	More or less. Expert Review of Clinical Immunology, 2015, 11, 875-876.	3.0	0
11	Sublingual Immunotherapy for Asthma: Affects T-Cells but Does not Impact Basophil Activation. Pediatric, Allergy, Immunology, and Pulmonology, 2014, 27, 17-23.	0.8	17
12	Toxicological assessment of kretek cigarettes part 5: Mechanistic investigations, inhalation toxicity. Regulatory Toxicology and Pharmacology, 2014, 70, S54-S65.	2.7	5
13	Role of mast cells in mucosal diseases: current concepts and strategies for treatment. Expert Review of Clinical Immunology, 2013, 9, 53-63.	3.0	17
14	The intricate association between gut microbiota and development of Type 1, Type 2 and Type 3 diabetes. Expert Review of Clinical Immunology, 2013, 9, 1031-1041.	3.0	66
15	Lung Inflammatory Effects, Tumorigenesis, and Emphysema Development in a Long-Term Inhalation Study with Cigarette Mainstream Smoke in Mice. Toxicological Sciences, 2013, 131, 596-611.	3.1	20
16	Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease. Expert Review of Clinical Immunology, 2013, 9, 1055-1068.	3.0	62
17	Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: Implications for treatment. European Journal of Medical Research, 2010, 15, 27-35.	2.2	42
18	Antioxidant defence during cardiopulmonary bypass surgery. European Journal of Cardio-thoracic Surgery, 2005, 27, 611-616.	1.4	50

#	ARTICLE	IF	CITATIONS
19	The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. <i>Respiratory Medicine</i> , 2005, 99, 241-249.	2.9	52
20	Use of ICAM-1 antibodies and antisense oligonucleotides to inhibit transmigration of neutrophils. <i>Inflammation Research</i> , 2004, 53, 143-149.	4.0	8
21	Inhibitory capacity of different steroids on neutrophil migration across a bilayer of endothelial and bronchial epithelial cells. <i>European Journal of Pharmacology</i> , 2003, 477, 261-267.	3.5	22
22	Segmental allergen challenge induces plasma protein leakage into the airways of asthmatic subjects at 4 hours but not at 5 minutes after challenge. <i>Translational Research</i> , 1999, 134, 74-82.	2.3	14
23	Oxidatively modified proteins in bronchoalveolar lavage fluid of patients with ARDS and patients at risk for ARDS. <i>European Respiratory Journal</i> , 1999, 13, 169.	6.7	60
24	Evidence for marked eosinophil degranulation in a case of eosinophilic pneumonia. <i>Respiratory Medicine</i> , 1996, 90, 505-509.	2.9	3
25	Potential role of Clara cell protein, an endogenous phospholipase A ₂ inhibitor, in acute lung injury. <i>European Respiratory Journal</i> , 1995, 8, 1647-1653.	6.7	91
26	Plasma protein leakage and local secretion of proteins assessed in sputum in asthma and COPD. The effect of inhaled corticosteroids. <i>Clinica Chimica Acta</i> , 1995, 240, 163-178.	1.1	16
27	Angiotensin-converting enzyme activity in serum and bronchoalveolar lavage fluid after damage to the alveolo-capillary barrier in the human lung. <i>Intensive Care Medicine</i> , 1993, 19, 390-394.	8.2	3
28	Nitroprusside, a nitrogen oxide generating drug, inhibits release of histamine and tryptase from human skin mast cells. <i>Agents and Actions</i> , 1993, 38, C237-C238.	0.7	13
29	Histamine and tryptase in serum of patients after coronary surgery: influence of pretreatment with methylprednisolone. <i>Agents and Actions</i> , 1993, 38, C278-C280.	0.7	0
30	Muramyl dipeptide and granulocyte-macrophage colony-stimulating factor enhance interferon- γ -induced nitric oxide production by rat alveolar macrophages. <i>Agents and Actions</i> , 1993, 38, 100-105.	0.7	19
31	Interleukin-8 Production in Patients Undergoing Cardiopulmonary Bypass: The Influence of Pretreatment with Methylprednisolone. <i>The American Review of Respiratory Disease</i> , 1993, 148, 890-895.	2.9	109
32	Pterins inhibit nitric oxide synthase activity in rat alveolar macrophages. <i>British Journal of Pharmacology</i> , 1992, 107, 1088-1091.	5.4	13
33	Release of arachidonic acid metabolites from isolated human alveolar type II cells. <i>Prostaglandins</i> , 1992, 44, 101-110.	1.2	16
34	Soybean trypsin inhibitor and α -amylase induce alveolar macrophages to release nitrogen oxides. <i>Biochemical Pharmacology</i> , 1992, 44, 387-390.	4.4	3
35	Synergism between interleukin-1 β and interferon- γ , an inducer of nitric oxide synthase, in rat lung fibroblasts. <i>European Journal of Pharmacology</i> , 1992, 224, 7-12.	3.5	61
36	Tumor necrosis factor α a novel stimulus for human skin mast cells to secrete histamine and tryptase. <i>Agents and Actions</i> , 1992, 36, C256-C259.	0.7	1

#	ARTICLE	IF	CITATIONS
37	L-Arginine-dependent production of nitrogen oxides by rat pulmonary macrophages. European Journal of Pharmacology, 1991, 200, 205-209.	3.5	115
38	Tumour necrosis factor stimulates human skin mast cells to release histamine and tryptase. Clinical and Experimental Allergy, 1991, 21, 711-714.	2.9	71
39	Some aspects of mast cell subtypes from human lung tissue. Agents and Actions, 1990, 30, 24-29.	0.7	4
40	A modified method for isolating viable alveolar type II cells from human lung tissue. Journal of Immunological Methods, 1990, 132, 145-146.	1.4	4
41	Mediator release from human lung mast cell subtypes in chronic bronchitis and emphysema. Agents and Actions, 1989, 27, 97-100.	0.7	4
42	Mast cell subtypes from human lung tissue: Their identification, separation, and functional characteristics. Agents and Actions, 1988, 23, 227-229.	0.7	7